Tilaksin 3's 125 mg coated tablets

The instruction for medical use of TILAKSIN medicine the Trade name Tilaksin Mezhdunarodnoye the unlicensed name Tiloron Lekarstvennaya the Tablet form, coated Structure One tablet contains active agent: tiloron 125.0 mg, excipients: hydrophosphate calcium dihydrate, gipromeloza, microcrystalline cellulose, povidone, silicon dioxide colloidal, potato starch, sodium of a kroskarmeloz, polyethyleneglycol, calcium stearate, talc, structure of a cover: film cover of Aquarius Preferred white (gipromeloza, kopovidon, polydextrose, polyethyleneglycol, srednetsepochny triglycerides, titanium dioxide (E171)), kandurin (titan dioxide (E171), potassium aluminosilicate (E555)), yellow decline dye (E110). The description of the Tablet of round shape, with a biconvex surface, coated orange color, on a break two layers are visible. Pharmacotherapeutic group Immunomodulators. Immunostimulators. Other immunostimulators. The ATX L03AX code the Pharmacological Pharmacokinetics Later properties of intake tiloron is quickly soaked up from a digestive tract. The bioavailability is 60%. About 80% of drug contact proteins of plasma. Drug is not exposed to biotransformation and does not collect in an organism. It is removed practically in not changed view with a stake and urine in the ratio 7:1. Elimination half-life makes 48 hours. Tilaksin's pharmacodynamics (tiloron) – immunomodulatory and antiviral means. Stimulates education in an organism of a, b, g - interferon. The main producers of interferon in response to administration of drug are intestines epithelium cells, hepatocytes, T lymphocytes, neutrophils and granulocytes. After intake the maximum products of interferon are defined in the sequence intestines-liver-blood in 4-24 hours. Stimulates stem cells of marrow, depending on a dose strengthens antibodyformation, reduces immunosuppression degree, restores a ratio T suppressors / T-helpery. It is effective concerning a wide range of viral infections, including against influenza viruses, other acute respiratory viral infections, hepatitis A, B, C and gerpesvirus. The mechanism of anti-virus action is connected with inhibition of broadcast of virus-specific proteins in the infected cells owing to what the reproduction of viruses is oppressed. When carrying out researches on animals (chicken and duck embryos) the high antiviral activity of drug concerning the causative agent of highly pathogenic avian influenza (VPPG) of a strain H5N1 and also (is proved when carrying out experiments on hens) the considerable immunostimulating and adjuvant activity concerning VPPG activator antigens. Indications as a part of complex therapy - treatment and prevention of flu and the acute respiratory viral infections (ARVI) - treatment of a herpes infection. The route of administration and doses take the Drug inside, after a meal. At treatment of flu and SARS: in the first 2 days of treatment - on 1 tablet (125 mg) a day, then – on 1 tablet (125 mg) every 48 hours. A course dose – 6 tablets (750 mg) for 10 days. For prevention of flu and a SARS: 1 tablet (125 mg) once a week for 6 weeks. For treatment of a herpes infection: in the first 2 days of treatment - on 1 tablet (125 mg) a day, then – on 1 tablet (125 mg) every 48 hours. A course dose – 20 tablets (2.5 g) for 38 days. Side effects - allergic reactions (rash, an itching, urticaria, a Quincke's disease) - the dispepsichesky phenomena (nausea, heartburn, feeling of weight and swelling in a stomach) - short-term fever If any of the side effects specified in the instruction are aggravated, or you noticed any other side effects which are not specified in the instruction, report about it to the doctor. Contraindications - hypersensitivity to any component of drug - pregnancy and the period of a lactation - children's and teenage age up to 18 years Medicinal interactions Tiloron is compatible to antibiotics and means of traditional treatment of viral and bacterial diseases. Clinically significant interaction of a tiloron with antibiotics and means of traditional treatment of viral and bacterial diseases and also with alcohol is not revealed. Special instructions If reception of the next dose of drug is missed, then follows without a time interval as soon as possible and without doubling of a dosage to continue a course of administration of drug Tilaksin on the begun scheme. If at treatment of flu and other SARS the drug Tilaksin within 5 days from the beginning of therapy does not note medical effect, it is necessary to see a doctor. The feature of influence of medicine on ability to run the vehicle or potentially dangerous Tilaksin mechanisms does not affect ability of control of vehicles and performance of potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions. Overdose overdose Cases are not known for the drug Tilaksin. The form of release and packing On 3 or 5 tablets pack into blister strip packaging from a film of polyvinylchloride and aluminum foil. On 1 or 2 blister strip packagings together with the instruction for medical use in the Kazakh and Russian languages place in a cardboard pack. To Store storage conditions at a temperature not above 25 °C. To store out of children's reach! Period of storage 4 years. Not to apply after expiry date. Prescription status Without prescription. VIVA Pharm LLP producer, Republic of Kazakhstan 2nd Ostroumova St., 33, Almaty the Owner of the registration certificate of VIVA-Interkhim LLP, Republic of Kazakhstan 2nd Ostroumova St., 33, Almaty the Address of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines and responsible for post-registration observation of safety of medicine: VIVA Pharm LLP, Republic of Kazakhstan 2nd Ostroumova St., 33, Almaty, 050030